

## **Brineura, Tremfya and Zinplava will require prior authorization**

**Summary:** The injectable drugs Brineura, Tremfya and Zinplava will require prior authorization (PA), and all requests must be reviewed by Amerigroup Amerivantage (Medicare Advantage) for PA dates of service beginning on or after June 1, 2018.

Please refer to the Provider Self-Service tool for detailed authorization requirements. Go to <https://providers.amerigroup.com>, select **New Jersey**, then under *Provider Resources & Documents* and select **Quick Tools/Precertification Lookup Tool**.

Please note: These drugs may not be covered in all states. Providers must review their specific state for coverage because not all drugs in this update will apply to the state in which you participate.

Noncompliance with the new requirements may result in denied claims. PA requirements will be added to the following codes:

- C9014 — Injection, Injection, cerliponase alfa, 1 mg (Brineura)
- C9029 — Injection, guselkumab, 1 mg (Tremfya)
- J0565 — Injection, bezlotoxumab, 10 mg (Zinplava)

Please use one of the following methods to request PA:

- **Phone:** 1-844-799-4129
- **Fax:** 1-844-765-5160
- **Web:** <https://www.Availity.com>

Federal and state law, as well as state contract language including definitions and specific contract provisions/exclusions, take precedence over these PA rules and must be considered first when determining coverage.

### **What if I need assistance?**

If you have questions about this communication or need assistance with any other item, call Provider Services at 1-844-799-4129.

**<https://providers.amerigroup.com>**

Amerivantage Dual Coordination (HMO SNP) is a D-SNP plan with a Medicare contract and a contract with the State Medicaid program. Enrollment in Amerivantage Dual Coordination (HMO SNP) depends on contract renewal.